



TO WHOM IT MAY CONCERN

4 March 2020

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. The Novo Nordisk product supply organisation secures access to Novo Nordisk products for more than 30 million patients daily across the globe.

Novo Nordisk is constantly monitoring stock levels and logistic operations to provide ongoing Diabetes & Biopharm supply across the globe despite the current anxieties over the spread of Coronavirus and based on this **Novo Nordisk is currently able to ensure adequate supply to all markets.**

As a global healthcare company it is our responsibility to secure balanced product availability across the globe. As such, **Novo Nordisk does not recommend adding more Diabetes or Biopharm in-market stock beyond what has already been planned.** Increasing local stock levels can lead to global disruptions and obsolescence along the Global Supply Chain.

Novo Nordisk is constantly in dialogue with our Affiliates and supporting Health Authorities to identify channels in which Novo Nordisk products are the sole supplier. We are also conducting customer risk analyses to ensure that an immediate allocation plan is available in case of any interruption.

Kind Regards

Maziar Doustdar  
Executive Vice President  
International Operations

Novo Nordisk Health Care AG  
Thurgauerstrasse 36/38  
8050 Zürich  
Switzerland  
Tel. +41 (0)43 222 4300 Fax +41 (0)43 222 4341

**Novo Nordisk Health Care AG**  
International Operations

Thurgauerstrasse 36  
CH-8050 Zurich  
Switzerland

Telephone:  
+41 43 222 4300

Internet:  
[www.novonordisk.com](http://www.novonordisk.com)

Telefax:  
+41 43 222 4404